Kopran vs Peers
- Market cap
- ₹1,214 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹181.04 – ₹339.46
Kopran ranks 1st by market capitalisation among 1 Drug Manufacturers - General companies tracked by ATS. Its largest peers are Kopran. Its P/E of 22.5 compares with a peer median of 22.5.
Kopran vs Drug Manufacturers - General peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Kopran | 251.45 | -1.12% | 1,214 | 22.5 | 2.85 | 14.5% | +18.5% |
| Kopran | 251.45 | -1.12% | 1,214 | 22.5 | 2.85 | 14.5% | +24.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 9 October 2026. How this data is compiled.
Kopran peer comparison — frequently asked questions
Who are Kopran's competitors?
Kopran's listed peers in Drug Manufacturers - General include Kopran, ranked here by market capitalisation.
How does Kopran's P/E compare with its peers?
Kopran trades at a P/E of 22.5, against a median of 22.5 across the 1 Drug Manufacturers - General peers shown.
Which is the largest company among Kopran's peers?
By market capitalisation, the largest company in the group is Kopran at ₹1,214 crore, against ₹1,214 crore for Kopran.
Same Data For Peers
Trade Kopran With ATS
Track KOPRAN live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.